PhytoMedical Technologies, Inc.’s Patented Anti-Cancer Compound Eradicates Tumor in Successful In-Vivo Tests against Human Brain Cancer

Published: Feb 03, 2009

PRINCETON, N.J.--(BUSINESS WIRE)--PhytoMedical Technologies, Inc. (OTCBB: PYTO) (FWB: ET6), today announced favorable results from recent in vivo efficacy and toxicity tests where the Company’s patented anti-cancer compound was administered to specimens with difficult-to-treat human brain cancer (SF295 glioblastoma xenografts) and, according to researchers, proved to be least toxic and extremely effective in controlling the growth of SF295 human glioblastoma xenografts.

Back to news